AbbVie | ABBV - Ordinary Share Capital


AbbVie reported $1.77B in Ordinary Share Capital for its fiscal quarter ending in June of 2025.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Abbott USD 1.74B 2.94M Mar/2026
ALKERMES USD 167.54M 1.08M Jun/2026
Amgen USD 541M 1000K Jun/2026
AstraZeneca USD 1.55B 44K Jun/2026
Biogen USD 146.7M 200K Sep/2025
BioMarin Pharmaceutical USD 193.27M 969K Mar/2026
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Coherus Biosciences USD 121.16M 4.92M Dec/2025
Eisai JPY 282.46M 345K Jun/2026
Eli Lilly USD 943.5M 3.33M Mar/2026
Gilead Sciences USD 1.24B 1000K Jun/2026
GlaxoSmithKline GBP 4.08B 20.6M Jun/2026
J&J USD 2.41B 1.35M Mar/2026
Medtronic USD 1.28B 1.38M Dec/2025
Merck USD 2.47B 4.93M Mar/2026
Neurocrine Biosciences USD 100.55M 50K Jun/2026
Novartis USD 1.9B 7.38M Jun/2026
Pacira USD 39.82M 512K Jun/2026
Perrigo USD 138.1M 500K Mar/2026
Pfizer USD 5.7B 0 Jun/2026
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Roche Holding CHF 796.77M 1.15M Jun/2026
Sanofi EUR 1.21B 8.25M Mar/2026
UCB EUR 190.36M 365.15K Dec/2025
Ultragenyx Pharmaceutical USD 98.3M 1.7M Mar/2026
United Therapeutics USD 42.16M 1.49M Mar/2026
Vertex Pharmaceuticals USD 253.3M 900K Jun/2026
Zoetis USD 420.35M 4.58M Mar/2026